Cantabria Labs Opens a New R&D&I Centre in Madrid

Following the renewal of its agreement with the American MIT for three more years, Cantabria Labs has announced the opening of its own research, development and innovation (R&D&I) centre in the Madrid complex of MaSID (Madrid Science Innovation District), based in Tres Cantos.

The new Cantabria Labs laboratory has been prepared by MaSID based on the company’s needs and, they say in a statement, “it has the most modern infrastructure and cutting-edge resources to contribute to the development of new ingredients and proprietary technologies.”

The 500-square-metre R&D space at MaSID will enable the company to optimise the resources dedicated to basic research, instrumental techniques and formulation for the development of pharmacological products, as well as cosmeceuticals and food supplements.

Cantabria Labs had a turnover of 293 million euros in 2022, 21% more than the previous year

The Spanish company closed 2022 with a turnover of 293 million euros, which represents an increase of 21% compared to 2021 , as announced last year by Susana Rodríguez, CEO of Cantabria Labs.

CAntabria Labs is present in more than 85 countries, has its own subsidiaries in eight of them, and manufactures and distributes more than 35 million units of the product annually . Also in 2022, the pharmaceutical company announced the launch in Spain, Italy and Portugal of Alocare solution, a drug with the first topical finasteride registered in Europe, indicated for the treatment of androgenic alopecia which, until now, was administered only orally.

MaSID is the first private science and innovation district created in Spain that offers services that are not present in any other hub for the development of Life Science and R&D projects. With its spaces in Tres Cantos and Fuencarral, it is positioned as a technological enclave specialized in the advancement and development of science for companies such as Cantabria Labs.

__

(Featured image by Florian Wahde via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us